Literature DB >> 19593165

Adalimumab-induced autoimmune hepatitis.

Tomer Adar1, Meir Mizrahi, Orit Pappo, Anat Scheiman-Elazary, Oren Shibolet.   

Abstract

Antitumor necrosis factor antibodies are widely used in the treatment of autoimmune diseases. We describe the occurrence of autoimmune hepatitis in a patient treated with adalimumab, a fully human IgG antibody against tumor necrosis factor, for psoriatic arthritis. The patient made a full recovery after discontinuation of adalimumab and treatment with steroids. This is the first reported case of adalimumab-induced autoimmune hepatitis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19593165     DOI： 10.1097/MCG.0b013e3181a745e7

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


  20 in total

Review 1.  Autoimmune hepatitis: a review.

Authors:  Andrea A Gossard; Keith D Lindor
Journal:  J Gastroenterol       Date:  2012-04-17       Impact factor: 7.527

Review 2.  Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.

Authors:  A Grasland; R Sterpu; S Boussoukaya; I Mahe
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

3.  Severe cholestasis due to adalimumab in a Crohn's disease patient.

Authors:  Edward Kim; Brian Bressler; David F Schaeffer; Eric M Yoshida
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.

Authors:  Susana Rodrigues; Susana Lopes; Fernando Magro; Hélder Cardoso; Ana Maria Horta e Vale; Margarida Marques; Eva Mariz; Miguel Bernardes; Joanne Lopes; Fátima Carneiro; Guilherme Macedo
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

6.  Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Authors:  Agustin Castiella; Eva Zapata; M Isabel Lucena; Raúl J Andrade
Journal:  World J Hepatol       Date:  2014-04-27

Review 7.  Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.

Authors:  Ora Shovman; Shalev Tamar; Howard Amital; Abdulla Watad; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2017-10-23       Impact factor: 2.980

Review 8.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

Review 9.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

Review 10.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.